Dr. Kelley Discusses the Rising Incidence of HCC

R. Kate Kelley, MD
Published: Tuesday, Mar 20, 2018



R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the rising incidence of hepatocellular carcinoma (HCC).

Obesity is a growing problem worldwide, and having obesity and risk factors for metabolic syndrome, including diabetes and dyslipidemia, can lead to HCC. Obesity can lead to a condition called nonalcoholic fatty liver disease, which is a spectrum of diseases, such as steatohepatitis.

Just like alcoholic hepatitis, hepatitis B, and hepatitis C, steatohepatitis can lead to fibrosis, cirrhosis, and the accumulation of mutations that can eventually lead to cancer. Associated conditions with nonalcoholic fatty liver disease are now the number 1 cause of HCC in the United States, says Kelley.
SELECTED
LANGUAGE


R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the rising incidence of hepatocellular carcinoma (HCC).

Obesity is a growing problem worldwide, and having obesity and risk factors for metabolic syndrome, including diabetes and dyslipidemia, can lead to HCC. Obesity can lead to a condition called nonalcoholic fatty liver disease, which is a spectrum of diseases, such as steatohepatitis.

Just like alcoholic hepatitis, hepatitis B, and hepatitis C, steatohepatitis can lead to fibrosis, cirrhosis, and the accumulation of mutations that can eventually lead to cancer. Associated conditions with nonalcoholic fatty liver disease are now the number 1 cause of HCC in the United States, says Kelley.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Show Me the Data™: Leveraging Evidence to Optimize Applications of PARP Inhibitor Strategies in Ovarian CancerJun 29, 20191.5
Publication Bottom Border
Border Publication
x